ANL Stock Forecast & Price Target

Adlai Nortye is attractive because it combines clinically validated RAS biology with multiple differentiated shots on goal, led by AN9025 and AN4035 in large, mutation-driven solid tumors. The FDA’s “Study-May-Proceed” letter and first patient dosed in Australia for AN4035 remove a key regulatory overhang, while the platform’s tumor-localized design aims to improve the therapeutic window versus systemic pan-RAS inhibition. The company also appears undervalued relative to RAS peers, with a market cap around $0.7 billion versus RevMed’s $35 billion and Erasca’s $3.8 billion, and a positive 1H27 AN9025 catalyst could help re-rate the shares.

Adlai Nortye is viewed negatively because its lead pan-RAS program, AN9025, still lacks clinical validation despite strong preclinical data, and its higher affinity and longer half-life could translate into toxicity that limits dosing, combinations, and commercial appeal. The company also faces meaningful IP and freedom-to-operate risk in the highly sensitive panRAS(ON) space, which could constrain strategic interest until clinical and legal clarity improves. More broadly, the provided commentary highlights class-wide concerns for RAS inhibitors—on-target toxicity in healthy cells, dose interruptions and reductions, and potentially modest efficacy versus benchmark standards—undermining the investment case.